Vanda Pharmaceuticals (VNDA) Asset Utilization Ratio (2011 - 2026)
Vanda Pharmaceuticals recorded quarterly Asset Utilization Ratio of 0.47 in Q1 2026, up 19.09% quarter-over-quarter from 0.4 in Q4 2025, and up 51.03% year-over-year from 0.31 in Q1 2025.
Vanda Pharmaceuticals' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.47 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 51.03% year-over-year to 0.47; the TTM figure through Mar 2026 stood at 0.47 (up 51.03% YoY), while the FY2025 annual figure was 0.38, up 23.86% from the prior year.
- Asset Utilization Ratio came in at 0.47 for Q1 2026 at Vanda Pharmaceuticals, up from 0.4 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.47 in Q1 2026 to a low of 0.27 in Q1 2024.
- A 5-year average of 0.36 and a median of 0.35 in 2025 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio slumped 32.0% in 2024 and soared 51.03% in 2026, its largest moves.
- Vanda Pharmaceuticals' Asset Utilization Ratio stood at 0.41 in 2022, then dropped by 26.27% to 0.3 in 2023, then grew by 2.29% to 0.31 in 2024, then rose by 29.79% to 0.4 in 2025, then climbed by 19.09% to 0.47 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.47, 0.4, and 0.35 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 0.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.47 |
| Dec 31, 2025 | 0.40 |
| Sep 30, 2025 | 0.35 |
| Jun 30, 2025 | 0.32 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.31 |
| Sep 30, 2024 | 0.29 |
| Jun 30, 2024 | 0.28 |
| Mar 31, 2024 | 0.27 |
| Dec 31, 2023 | 0.30 |
| Sep 30, 2023 | 0.33 |
| Jun 30, 2023 | 0.37 |
| Mar 31, 2023 | 0.40 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.42 |
| Jun 30, 2022 | 0.43 |
| Mar 31, 2022 | 0.44 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 0.47 |
| Jun 30, 2021 | 0.47 |
| Mar 31, 2021 | 0.47 |
| Dec 31, 2020 | 0.47 |
| Sep 30, 2020 | 0.47 |
| Jun 30, 2020 | 0.48 |
| Mar 31, 2020 | 0.49 |
| Dec 31, 2019 | 0.47 |
| Sep 30, 2019 | 0.52 |
| Jun 30, 2019 | 0.58 |
| Mar 31, 2019 | 0.58 |
| Dec 31, 2018 | 0.60 |
| Sep 30, 2018 | 0.60 |
| Jun 30, 2018 | 0.57 |
| Mar 31, 2018 | 0.66 |
| Dec 31, 2017 | 0.80 |
| Sep 30, 2017 | 0.76 |
| Jun 30, 2017 | 0.75 |
| Mar 31, 2017 | 0.72 |
| Dec 31, 2016 | 0.70 |
| Sep 30, 2016 | 0.68 |
| Jun 30, 2016 | 0.63 |
| Mar 31, 2016 | 0.58 |
| Dec 31, 2015 | 0.51 |
| Sep 30, 2015 | 0.42 |
| Jun 30, 2015 | 0.37 |
| Mar 31, 2015 | 0.33 |
| Dec 31, 2014 | 0.40 |
| Sep 30, 2014 | 0.53 |
| Jun 30, 2014 | 0.36 |
| Mar 31, 2014 | 0.26 |
| Dec 31, 2013 | 0.23 |
| Sep 30, 2013 | 0.24 |
| Jun 30, 2013 | 0.27 |
| Mar 31, 2013 | 0.25 |
| Dec 31, 2012 | 0.23 |
| Sep 30, 2012 | 0.21 |
| Jun 30, 2012 | 0.20 |
| Mar 31, 2012 | 0.18 |
| Dec 31, 2011 | 0.17 |
| Sep 30, 2011 | 0.09 |